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Failure to objectively assess the effect of digitalis on exercise 
capacity has resulted in controversy regarding its use in 
patients with chronic congestive heart failure. To clarify 
this situation, maximal treadmill testing with respiratory 
gas exchange analysis was performed on 11 patients (mean 
age 57 f 9 years) with chronic congestive heart failure with 
and without digoxin therapy. Ten of the 11 had a consistent 
third sound gallop, and the mean ejection fraction of the 
group was 24 + 10%. Rest heart rate was significantly 
higher (91 f 16 versus 102 f 16 beats/mitt; p < 0.05) and 
rest systolic blood pressure was significantly reduced in the 
absence of digoxin (130 f 23 versus 121 f 15 mm Hg; p < 
0.05). No differences in heart rate or blood pressure were 
observed during exercise. 
Significant increases in ventilatory oxygen uptake were 
observed with digoxin submaximally (3.0 mph, 0% grade), 
at the gas exchange anaerobic threshold and at maximal 
exercise (mean increase of 2.6 ml/kg per mitt; p < 0.02). An 
improvement in the estimated ratio of ventilatory dead 
space to tidal volume (VD/VT), an index of physiologic 
efficiency, occurred throughout exercise during digoxin 
therapy, and there was a significant negative correlation 
between the change in maximal oxygen uptake and change 
in maximal estimated VDlVT (r = -0.63; p < 0.05). Thus, 
digoxin therapy is associated with a significant improve- 
ment in exercise capacity in patients with chronic heart 
failure, most likely due to an improved matching of venti- 
lation to perfusion. 
(J Am Co11 Cardiol1989;13:113843) 
Digitalis glycosides have played a role in the treatment of 
congestive heart failure for 2 centuries. However, studies (l- 
7) have not consistently documented a beneficial hemody- 
namic effect nor has exercise testing documented objective 
improvements, Thus, as pointed out by a recent symposium 
(8) on therapeutic challenges in congestive heart failure, 
there has been controversy regarding the use of digitalis 
since it was introduced in 1785. The inclusion of patients 
limited by angina, the concomitant use of beta-adrenergic 
blocking agents and the failure to include respiratory gas 
exchange analysis have limited the interpretation of exercise 
studies evaluating digoxin (26-9). In this study the effect of 
digoxin on exercise performance in patients with congestive 
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heart failure was assessed objectively with the use of respir- 
atory gas exchange analysis. 
Methods 
Study patients. Eleven male volunteers ranging in age 
from 41 to 75 years (mean 57 ? 9) participated in the study. 
Patients were recruited from a cardiomyopathy clinic and 
each had a history of congestive heart failure due to systolic 
dysfunction documented clinically and by noninvasive test- 
ing. Clinical characteristics and medications are listed in 
Table 1. All patients were in normal sinus rhythm and 
classified in New York Heart Association functional class II 
or III. None had a recent history of exertional angina. All 
rights and privileges were honored in accordance with an 
established human subjects protocol and informed consent 
was obtained. 
Study design. Ten patients receiving long-term digoxin 
therapy were initially stabilized to a therapeutic serum 
digoxin level with the use of radioimmunoassay (0.5 to 1.7 
ng/ml) and exercise tests were performed 4 to 6 h after the 
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Table 1. Clinical Characteristics of the 11 Patients 
Patient 
Age 
(yr) 
Cardiomyopathy 
Type 
Ejection 
Fraction 
(%I 
NYHA 
Class 
Digoxin 
Serum 
Dosage Level 
tmgidayl tngimll Concomitant Medication 
1 65 Idiopathic 
2 55 Aortic valve 
3 61 lschemic 
4 51 Ischemicialcoholic 
5 75 lschemic 
6 45 Idiopathic 
7 57 lschemic 
8 63 lschemic 
9 50 Idiopathic 
IO 51 Ischemic 
11 64 Alcoholic 
NYHA = New York Heart Association. 
38 II 
38 II 
II II 
29 II 
I8 III 
30 II 
26 111 
19 111 
30 II 
14 III 
I4 III 
morning digoxin dose. A follow-up exercise test was ob- 
tained after a 2 to 4 week washout period without digoxin. In 
one patient being treated only with diuretics, oral digoxin 
therapy was instituted after his initial exercise test, and an 
exercise test was performed 3 weeks later. All patients had 
previous treadmill experience before the study. No patient 
had detectable serum digoxin levels during the period they 
were not taking digoxin. To maintain body weight, three 
patients required an increased diuretic dosage while they 
were not taking digoxin but were clinically stable at the time 
of follow-up testing. 
Exercise tests. Patients were exercised on a calibrated 
motor-driven treadmill and instructed to abstain from food, 
coffee and cigarettes for at least 3 h before testing. From 
previous treadmill tests, individualized protocols were de- 
signed for each patient utilizing guidelines outlined by Buch- 
fuhrer et al. (10). The patients’ subjective perception of 
exertion was evaluated with use of the Borg 6 to 20 point 
scale (I 1). All exercise tests were continued to volitional 
fatigue or dyspnea, or both. No exercise test was limited by 
angina pectoris. 
Respiratory gas exchange variables were determined 
continuously throughout exercise with use of the Medical 
Graphics Corp. 2001 system. The reproducibility of the 
metabolic system employed in the present study was docu- 
mented by techniques outlined by Jones and Campbell (12) 
with <lo’% variability in respiratory variables observed in 
four laboratory personnel over a 6 month period. A standard 
12 lead electrocardiogram (ECG) and blood pressure with 
the use of a clinical sphygmomanometer were obtained at 
rest and throughout the exercise and recovery periods. 
Points of analysis. Hemodynamic and respiratory varia- 
bles and perceived exertion were analyzed at 4 min of 
exercise, at the gas exchange anaerobic threshold and at 
maximal exertion. Respiratory gas exchange variables in- 
0.125 
0.375 
0.125 
0.375 
0.125 
O.?.FO 
0.375 
0.375 
0.250 
0.250 
0.250 
I .40 Lasix. quinaglute 
1.00 Lasix 
0.70 Lasix. Isordil, chlorpropamide 
0.80 Isordil. nitropaste 
I .30 Lasix 
0.50 Lasix 
1.53 Lasix. captopril, lsordil 
0.80 Lasix, metolazone, Isordil. captopril 
1.20 Maxzide, allopurinol. captopril 
I .40 Lasix. captopril, allopurinol 
1.90 Captopril, Lasix. chlopropamide 
eluded ventilation (liters/mitt; BTPS), oxygen uptake (V02, 
ml/kg per min; STPD), carbon dioxide production @CO,, 
litersimin; STPD), respiratory exchange ratio (representing 
VCO,/VO& tidal volume (VT) (ml/breath), an estimated 
ratio of the volume of dead space (VD) to tidal volume (VDi 
VT) calculated with the use of end-tidal pressure of carbon 
dioxide as outlined by Jones and Campbell (12), respiratory 
rate and oxygen pulse (ml/beat). The gas exchange anaerobic 
threshold was determined by two independent observers as 
outlined by Sullivan et al. (13). 
Statistical analysis. Data were entered into a Lotus 123 
spreadsheet, analyzed with use of the Student’s t test for 
paired observations from Statistical Graphics Corp. soft- 
ware, and presented as mean values 2 SD with p < 0.05 
considered significant. 
Results 
No undue symptoms or complications were observed 
during exercise testing or with discontinuation of digoxin 
therapy. Table 2 presents hemodynamic and gas exchange 
data during exercise with and without digoxin therapy. 
Figures 1 and 2 illustrate oxygen uptake with and without 
digoxin therapy at the gas exchange anaerobic threshold and 
maximal exercise, respectively. Figure 3 illustrates the rela- 
tion between change in maximal oxygen uptake and change 
in VD/VT with and without digoxin therapy. 
Rest. No significant differences were noted in values with 
or without digoxin therapy for body weight, supine heart 
rate, systolic blood pressure or diastolic blood pressure. 
Standing heart rate was significantly increased (102 % 16 
versus 91 + 16 beats/mitt; p < 0.05) and standing systolic 
blood pressure was significantly decreased (121 2 I5 versus 
130 ? 23 mm Hg; p < 0.05) in the absence of digoxin 
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Table 2. Hemodynamic and Gas Exchange Data During Exercise With and Without Digoxin Therapy in 11 Patients 
Submaximal Exercise (n = 1 I) ATge (n = 10) Maximal Exercise (n = I I) 
With Without With Without With Without 
Heart rate (beats/min) 
Systolic blood pressure (mm Hg) 
Diastolic blood pressure (mm Hg) 
Oxygen uptake (ml/kg per min) 
CO, production (Literslmin) 
Respiratory exchange ratio 
Ventilation (liters/min) 
Total volume (ml) 
Respiratory rate (per min) 
VDNT 
Oxygen pulse 
Perceived exertion 
Total treadmill time (s) 
117 (II) 
149 (25) 
70 (26) 
12.8 (1.8)* 
0.933 (0.28) 
0.84 (0.07) 
39.3 (11.9) 
1,525 (382) 
27 (8) 
0.27 (0.06)* 
9.6 (2.6)* 
12 (2) 
II9 (14) 
142 (22) 
80 (12) 
10.8 (0.8) 
0.813 (0.17) 
0.88 (0.10) 
40.9 (12) 
I.392 (294) 
30 (9) 
0.31 (0.06) 
8.0 (2.5) 
12 (2) 
118 (13) 
I51 (26) 
78 (14) 
13.8 (2.6)t 
0.984 (0.29) 
0.83 (0.06) 
38.6 (6.0) 
1,512 (277) 
26 (6) 
0.28 (0.06) 
10.1 (2.8)* 
12 (3) 
112 (14) 
147 (25) 
79 (14) 
11.6 (1.6) 
0.876 (0.24) 
0.87 (0.05) 
40.1 (8.5) 
1,434 (367) 
29 (7) 
0.31 (M) 
8.5 (2.0) 
13 (3) 
143 (15) 
I66 (31) 
79 (14) 
19.3 (4.2)* 
1.758 (0.590)* 
1.03 (0.05) 
74.2 (19.5) 
2,010 (392) 
37 (7) 
0.26 (0.06) 
11.8 (33.3)* 
19 (1) 
537 (133) 
142 (16) 
154 (34) 
77 (13) 
16.7 (4.5) 
1.569 (0.62) 
I .06 (0.06) 
74.2 (20.1) 
1,906 (462) 
39 (8) 
0.27 (0.07) 
10.3 (3.5) 
19 (1) 
495 (151) 
*p < 0.01 with digoxin versus without digoxin; tp < 0.02 with digoxin versus without digoxin. ATge = gas exchange anaerobic threshold; VDNT = 
ventilatory dead space/tidal volume ratio; With and Without = with and without digoxin therapy, respectively; values in parentheses are + SD. 
therapy. No change in standing diastolic blood pressure 
occurred. 
Exercise. Hemodynamic and respiratory variables ob- 
served on and off digoxin at a submaximal work load 
corresponding to 4 minutes of exercise, gas exchange anaer- 
obic threshold and maximal exercise are outlined in Table 2. 
Figure 1. Maximal oxygen uptake (?O,) at the gas exchange 
anaerobic threshold (AT,,) with and without digoxin therapy. 
25 
P 
The gas exchange anaerobic threshold could not be reliably 
determined in 1 patient without digoxin; thus data from 10 
patients are reported. Significant increases in oxygen uptake 
(Fig. 1 and 2) and oxygen pulse were noted with digoxin at 
each point of analysis. Ventilation did not differ significantly 
with or without digoxin at any of these exercise levels. 
Although total treadmill time increased with digoxin, the 
difference was not statistically significant. Maximal carbon 
Figure 2. Maximal oxygen uptake (irO,),with and without digoxin 
therapy. 
30 
25 
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OIQOX IN Dla"o"X!N 
OFF 
DIGOXIN DdTXlN 
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Figure 3.. Relation between change in maximal oxygen 
uptake (VO,) and change in maximal estimated ventila- 
tory dead space/tidal volume ratio (VD/VT) with and 
without digoxin therapy. 0 
0 
r=-.63; pc .05 
~~1.67 + (-47.2) X 
0 
-2-l 
L 
I I I I I 
-.05 -.04 -.03 -.02 -.Ol 0 .Ol .02 .03 
AMAXIMAL eat. V,lV, (ON-OFF DIGOXIN) 
dioxide production was significantly increased during digox- 
in administration. 
A significant reduction in estimated VDIVT was observed 
on digoxin at the submaximal work load. This variable was 
similarly reduced with digoxin at the gas exchange anaerobic 
threshold and maximal exercise but did not reach statistical 
significance (p < 0.07 at maximal exercise). Additional 
trends observed with respect to ventilation included an 
increased tidal volume and decreased respiratory rate during 
exercise when patients were tested while taking digoxin. No 
significant change in the patients’ subjective perception of 
effort was observed with or without digoxin therapy. 
A significant negative correlation was observed between 
the change in maximal estimated VDIVT and the change in 
maximal oxygen uptake (ml/kg per min) with and without 
digoxin (r = -0.63; p < 0.05) (Fig. 3). Neither rest ejection 
fraction (r = 0.01; NS) nor digoxin level (r = -0.30; NS) 
correlated with the change in maximal oxygen uptake during 
digoxin administration. 
Discussion 
Controversy exists as to the role of digoxin and inotropic 
agents in patients with heart failure (1-9). Most clinicians 
agree that digoxin is indicated in patients with heart failure 
or atria1 fibrillation. However, it has been debated whether 
digoxin is needed by patients with heart failure and sinus 
rhythm whose symptoms are controlled by diuretic or vaso- 
dilator therapy, or both. Review of current publications 
suggests that the beneficial effects of digoxin would most 
likely occur in patients with heart failure who have an 
audible third sound gallop and an elevated pulmonary cap- 
illary wedge pressure after a combination of diuretics or 
vasodilators, or both (1,4,5). 
increased oxygen uptake and pulmonary function on digox- 
in therapy. The present study demonstrated increased ven- 
tilatory oxygen uptake and improved pulmonary function 
during digoxin therapy in a homogeneous group of patients 
with heart failure (10 of 11 had an audible third sound gallop, 
all had an ejection fraction <40% and cardiomegaly on chest 
X-ray film). Many of the observed changes during exercise 
with digoxin therapy in the present study-that is, increased 
oxygen uptake, oxygen pulse and maximal carbon dioxide 
production-could be attributed to an increased cardiac 
output. This conclusion is supported by Gheorghiade et al. 
(5), who recently observed an increase in cardiac index in a 
similar subset of heart failure patients after digoxin, diuretic 
and vasodilator therapy. However, early data from Nieder- 
berger et al. (14) demonstrated that in patients with angina 
who were limited by left ventricular dysfunction, digoxin did 
not affect maximal oxygen uptake, cardiac output, stroke 
volume or arterial-venous oxygen difference. 
The increased oxygen uptake and oxygen pulse at a 
submaximal work load, gas exchange anaerobic threshold 
and maximal exertion could be explained by an increased 
cardiac output, an increased arterial-venous oxygen content 
difference, or both. Research (5,15) in similar populations 
treated with digoxin has demonstrated increases in stroke 
volume with subsequent increases in cardiac output. In the 
present study, heart rate did not differ significantly during 
exercise; therefore, the observed increases in oxygen uptake 
would appear to be related to increases in stroke volume. 
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Although an increase in the arterial-venous oxygen differ- 
ence is a plausible explanation, it would require either an 
increase in arterial oxygen saturation or a decrease in venous 
oxygen saturation, or both, during digoxin therapy. Because 
patients with chronic heart failure maintain normal arterial 
oxygen saturation during exercise and mixed venous oxygen 
saturation has been reported to be as low as 7%, the 
contribution these variables could make to the increased 
oxygen uptake observed would appear minimal. 
Previous studies. Frequently cited investigations (26-9) 
evaluating the effect of digoxin in patients with heart failure 
have failed to demonstrate any effect on exercise capacity. 
Fleg et al. (2) reported no change in treadmill exercise time 
in 12 patients with heart failure after digoxin administration. 
However, 3 patients were limited by angina and only 1 in the 
study group of 30 had a third sound gallop. The concomitant 
use of a beta-adrenergic blocking agent by four patients 
raises additional questions regarding this study, given the 
effect of beta-adrenergic blockade with respect to exercise 
capacity (16,17). Aronow et al. (7) observed no change in 
treadmill time in 10 elderly patients with heart failure, all 
with a third heart sound, after discontinuation of digoxin 
therapy. The increased age (mean 81 2 7 years), elevated 
ejection fraction (mean 44 + 5%) and observation that 4 of 
the 10 patients were unable to complete the first stage of a 
modified Bruce protocol limits this study. Guyatt et al. (18) 
recently reported small improvements in a 6 min walk test, 
but no change in bicycle exercise time in 20 patients with 
chronic congestive heart failure after 7 weeks of digoxin as 
compared with 7 weeks of placebo therapy. The lack of 
improvement in exercise time during digoxin therapy in the 
Captopril Digoxin Multicenter Research Group Trial (6) may 
be related to the limitations of using exercise time to 
evaluate exercise capacity (19) and the observation that a 
third sound gallop was present in only 40% of the patients 
treated with digoxin. 
In agreement with the present study, Alicandri et al. (20) 
reported a significant (18%) increase over baseline in mea- 
sured maximal oxygen uptake during digoxin therapy in 16 
patients with heart failure. It is not known, however, 
whether a third sound gallop was present, and a mean 
maximal oxygen uptake of 585 + 150 ml/min in the absence 
of digoxin suggests that most of these patients were in 
functional class III or IV. Goodman et al. (21) reported 
results similar to those of our findings in six patients with an 
ejection fraction of 19 2 8% in whom significant increases in 
maximal oxygen uptake and the gas exchange anaerobic 
threshold were observed during digoxin therapy relative to 
placebo. 
Role of dead space/tidal volume ratio in heart failure. The 
ventilation required for a given level of work is dependent on 
the ineffective fraction of the tidal volume (VT), that is, the 
ventilatory dead space (VD). This fraction, VDNT, is often 
elevated in patients with congestive heart failure, which 
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leads to an inappropriate matching of ventilation and perfu- 
sion. In obtaining VDIVT, arterial carbon dioxide pressure is 
estimated from the end-tidal carbon dioxide pressure. There- 
fore, in cases in which dead space is elevated, the end-tidal 
carbon dioxide pressure will be lowered, leading to an 
underestimation of arterial carbon dioxide and subsequent 
underestimation of VDIVT. Given this limitation, estimated 
VDlVT within the same patient can provide an indication of 
the contribution dead space is making with regard to venti- 
lation. Previously reported VDlVT values have ranged from 
0.37 to 0.40 for patients with heart failure in whom arterial 
carbon dioxide and respiratory gas exchange analysis was 
performed (22,23). These values are significantly higher than 
the estimated VDNT observed in the present study (Table 
2). The increase in estimated VDNT observed at submax- 
imal exercise in the absence of digoxin therapy in the present 
study provides support for the hypothesis that the increased 
ventilation with respect to oxygen uptake and carbon diox- 
ide production observed in patients with heart failure is 
related to increased physiologic dead space (22,23). 
Alternative explanations for the increased ventilation in 
patients with heart failure include increased alveolar venti- 
lation secondary to a decreased arterial carbon dioxide “set 
point” (24,25) and mismatching of ventilation and perfusion. 
Improved pulmonary blood flow secondary to increased 
cardiac output after digoxin administration may explain the 
observed decrease in estimated VDNT and negative corre- 
lation between changes in maximal oxygen uptake and 
maximal VDNT in the present study. 
Conclusions. The present study has documented a small 
but significant improvement in maximal oxygen uptake and 
gas exchange anaerobic threshold during digoxin therapy in 
a homogeneous group of patients in normal sinus rhythm 
with chronic heart failure. A reduction in estimated ventila- 
tory dead space/tidal volume ratio during submaximal exer- 
cise suggests that digoxin improves matching of ventilation 
and perfusion. 
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